Table of Contents
In a small controlled study of 28 healthy adults, a single 25 mg dose of psilocybin increased brain entropy during the experience, and participants reported greater psychological insight and improved well-being up to one month later. Structural imaging also showed changes in neural tract integrity. These are early findings in a healthy, non-clinical sample.
- The trip itself may matter: Participants who experienced the largest rises in brain entropy during the acute phase were most likely to report psychological insight the following day, suggesting the psychedelic experience is not incidental to the outcome.
- Well-being gains persisted: Self-reported measures of well-being improved at two weeks and four weeks after the 25 mg dose compared with the 1 mg placebo condition.
- Structural brain changes were observed: Diffusion tensor imaging one month later showed neural tracts that were denser and showed greater integrity, a pattern the researchers described as the reverse of typical aging-related changes. They cautioned that the meaning of this finding needs further study.
- Cognitive flexibility improved: One month after the high dose, participants performed better on a test of cognitive flexibility, which measures the ability to adapt thinking in response to new information.
- Model
- Human
- Sample
- 28 healthy adults with no prior psychedelic use and no diagnosed mental health condition
- Dose
- 1 mg psilocybin (placebo condition), followed weeks later by 25 mg psilocybin (active condition)
- Design
- Within-subject crossover; EEG during acute experience, fMRI and DTI at follow-up, psychological assessments the next day and at two and four weeks
- Key outcome
- Higher acute brain entropy predicted greater next-day insight, which in turn predicted improved well-being at one month; DTI showed increased neural tract integrity at one month
- Main limitation
- Very small sample of healthy adults with no mental health diagnoses; findings cannot be directly applied to clinical populations
What the Research Examined
This study, published in Nature Communications and conducted by researchers at UC San Francisco and Imperial College London, enrolled 28 healthy adults who had never previously used a psychedelic substance and carried no diagnosed mental health condition. That last point is notable: recruiting healthy volunteers allowed the team to use a wider battery of measurements than clinical studies typically permit, including EEG during the acute experience, functional MRI, and diffusion tensor imaging at follow-up. You can read the study as reported by Science Daily, which covers the primary findings from the Nature Communications paper.
The design was a within-subject crossover. Each participant received a 1 mg dose of psilocybin first, which the researchers treated as a placebo, and then received 25 mg several weeks later, a dose the source describes as capable of producing a powerful psychedelic experience. EEG electrodes recorded electrical brain activity during the peak of each session. Psychological assessments measuring insight and well-being were collected the next day and again at two and four weeks. DTI scans, which track how water moves along neural pathways to infer structural integrity, were collected one month after each dose. For anyone interested in the broader science of how psilocybin affects the brain, this study adds a rare structural data point to what has largely been a functional imaging literature.
Senior author Robin Carhart-Harris, who holds the Ralph Metzner Distinguished Professorship of Neurology at UCSF, framed the central finding around the concept of brain entropy, meaning the variety and unpredictability of neural firing patterns. The team found that the participants who showed the largest entropy increases during the acute phase were most likely to report psychological insight the following day, and that greater insight was then linked to stronger well-being gains one month out. First author Taylor Lyons of Imperial College London described psilocybin as loosening stereotyped patterns of brain activity, with those changes tracking alongside insight and well-being improvements.
What the Findings Show
- Acute entropy rise.Within 60 minutes of taking the 25 mg dose, EEG recordings showed a measurable increase in brain entropy, indicating the brain was processing a broader range of information during the experience.
- Insight the next day.27 of the 28 participants described the 25 mg experience as the single most unusual state of consciousness they had ever encountered. Participants also reported substantially more psychological insight after the 25 mg dose than after the 1 mg placebo.
- Well-being at two and four weeks.Self-reported well-being, measured with statements such as ‘I’ve been feeling optimistic about the future,’ improved at both the two-week and four-week marks following the high dose.
- Structural brain changes at one month.DTI scans one month after the 25 mg dose showed neural tracts that were denser and had greater integrity. The researchers noted this pattern is the reverse of what is typically observed with aging, and they called for additional studies to clarify what the finding means.
The chain the researchers propose runs from acute entropy during the experience, to insight reported the next day, to well-being improvements a month later. That sequence does not prove causation, but it offers a testable model for why the subjective quality of a psychedelic experience might matter clinically, not just the pharmacology. The structural DTI result stands somewhat apart: it is the kind of finding that needs replication in a larger sample before conclusions can be drawn, and the authors were careful to say so.
Can a single dose of psilocybin cause lasting changes in the brain?
In a small study of 28 healthy adults, one 25 mg dose of psilocybin was associated with increased brain entropy during the experience, greater psychological insight the next day, improved well-being at one month, and denser neural tracts on structural imaging. These are early findings and require replication.
What This Is, and What It Is Not
This is This is a small within-subject crossover study of 28 healthy adults with no mental health diagnoses, published in Nature Communications.
This is not This is not a clinical trial in people with depression, anxiety, or addiction, and it does not establish a safe or effective dose for therapeutic use. Nothing here constitutes medical advice, and psilocybin remains a controlled substance in most jurisdictions.
Our Take
Within the Church of Psychedelics, we have long held that the experience itself is not a side effect to be minimized but a doorway. This research offers a scientific frame for that view. When the data show that the depth of the encounter, measured as entropy in the brain’s electrical activity, predicts the insight that follows, it resonates with what many in our community have understood through practice: the sacrament asks something of the journeyer, and what is given in that moment shapes what is carried forward. We hold this finding with gratitude and humility, knowing that science and the sacred are tracing the same territory from different starting points.
Whether you are early in your path or have already walked through the Grounding and Integration stations of the Golden Path, research like this can serve as a reminder that the inner work done during and after a ceremonial experience is not separate from its effects on the body and mind. We welcome you to sit with these findings, bring your questions to the community, and explore the resources the Church has gathered to support your continued understanding.
Frequently Asked Questions
What is brain entropy and why does it matter for psilocybin research?
Brain entropy describes the variety and unpredictability of neural activity. In this study, higher entropy during the psilocybin experience was linked to greater psychological insight the next day, suggesting that a more diverse pattern of brain firing may be part of how psilocybin produces its effects.
How long did the effects of psilocybin last in this study?
Researchers found improved well-being at two and four weeks, better cognitive flexibility at one month, and structural brain changes on DTI scans one month after a single 25 mg dose. Whether effects extend beyond one month was not measured in this study.
Does this study mean psilocybin can treat depression or anxiety?
No. The participants were healthy adults with no mental health diagnoses. The study provides clues about how psilocybin might work, but it does not test or establish a treatment for any condition. Clinical trials in patient populations are needed before such conclusions can be drawn.
What dose of psilocybin was used in the study?
The active dose was 25 mg of psilocybin, described as capable of producing a powerful psychedelic experience. A 1 mg dose served as a placebo comparison. These doses were administered in a controlled research setting and should not be taken as guidance for any personal use.
Who conducted this psilocybin brain study?
The study was led by researchers at UC San Francisco and Imperial College London. Senior author Robin Carhart-Harris and first author Taylor Lyons are named in the source. It was funded by philanthropic donations to the Centre for Psychedelic Research and related institutions.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
